I. Dobler

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia

K. Kannan, R. Gregory, M. Levis, 2022, Haematologica.

Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity

Christopher J. Weber, James G. Bollinger, L. Shaw, 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay

G. Smithson, N. Vande Casteele, A. Suri, 2023, Therapeutic drug monitoring.

675 Measuring Serum Vedolizumab and Antibodies to Vedolizumab: Comparison of Four Commercially Available Clinical Laboratory Assays to the Assay Used in Vedolizumab Development

G. Smithson, Teresa Osborn, Li-li Yang, 2019, American Journal of Gastroenterology.

Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure

M. Karsdal, R. Moreau, R. Jalan, 2021, JHEP reports : innovation in hepatology.